🧬 Aging Wiki

Sunscreen and prevention of skin aging: a randomized trial

12 min read

Permanent verification note: This paper is closed-access (not_oa per a local paper archive). Abstract-level verification completed 2026-05-19 — bibliographic metadata, key quantitative outcomes (OR 0.76; 95% CI 0.59–0.98), study design, n=903, and 4.5-year follow-up all confirmed against PubMed efetch (PMID 23732711). Full-text methodological details (per-arm n, randomization procedure, scoring rubric, subgroup breakdown) remain unverifiable. no-fulltext-access

Sunscreen and prevention of skin aging: a randomized trial

Hughes MCB, Williams GM, Baker P, Green AC · Annals of Internal Medicine 2013;158(11):781–790 · doi:10.7326/0003-4819-158-11-201306040-00002 · PMID: 23732711

TL;DR

The longest and largest RCT to directly test sunscreen as a photoaging intervention. 903 Australian adults younger than 55 years were randomized in a 2×2 factorial design to daily versus discretionary SPF 15+ broad-spectrum sunscreen use, crossed with beta-carotene (30 mg/day) versus placebo supplementation. After 4.5 years, the daily sunscreen group showed significantly less skin aging than the discretionary group: relative odds of detectable aging progression = 0.76 (95% CI 0.59–0.98). Beta-carotene supplementation showed no overall effect on photoaging endpoints (with contrasting subgroup associations by baseline severity of aging not fully characterizable from the abstract). Outcome was objective microtopography of dermal elastosis on the dorsal hands (silicone cast grading by trained dermatologists). As of 2026, this remains the best-evidenced RCT supporting daily broad-spectrum sunscreen as an anti-photoaging intervention and is the primary empirical anchor for the uv-protection intervention page.

Background

Rationale for the trial

Prior to this trial, the evidence that daily sunscreen use prevents skin aging in humans was largely indirect: cross-sectional comparisons of sun-exposed versus sun-protected anatomical sites, twin studies comparing lifetime solar exposure, and mechanistic data showing that UV activates AP-1/NF-κB → MMP pathways at sub-erythemogenic doses in human skin 1. No adequately powered, long-duration RCT had tested whether daily preventive sunscreen use reduces objectively measurable skin aging progression in community-dwelling adults.

Population and setting

The trial was conducted in Nambour, Queensland, Australia (latitude ~26° S) — a high-UV-burden location representing one of the highest incidences of skin cancer and photoaging in the world. The community-based sample allowed enrollment of adults with a range of skin types and sun exposure habits. Enrollment occurred during the Nambour Skin Cancer Study (1992–1996), providing the infrastructure for this parallel RCT. The sample is fair-skinned, predominantly of Northern European descent — the highest-risk phototype group for UV-induced photoaging.

Methods

Design

2Ă—2 factorial randomized controlled trial. The two independent binary factors were:

  1. Sunscreen assignment: daily use of SPF 15+ broad-spectrum sunscreen (applied to head, neck, arms, and hands every morning; reapplied after swimming or heavy sweating) versus discretionary use (the control condition — subjects used sunscreen as they would naturally, typically for recreational sun exposure only).
  2. Beta-carotene supplementation: 30 mg/day beta-carotene capsule versus matched placebo capsule.

This yields four arms: (a) daily sunscreen + beta-carotene; (b) daily sunscreen + placebo; (c) discretionary sunscreen + beta-carotene; (d) discretionary sunscreen + placebo. The primary photoaging comparison is the marginal sunscreen effect (daily vs. discretionary), collapsed across the beta-carotene factor. The beta-carotene comparison is the marginal supplement effect, collapsed across sunscreen assignment.

Participants

  • n = 903 adults enrolled
  • Age range at enrollment: younger than 55 years (abstract does not state a lower bound; “25–55” in secondary sources is unconfirmed at abstract level — no-fulltext-access; mean not stated in abstract) — a deliberately younger-to-middle cohort to capture photoaging prevention, not reversal
  • Inclusion: community-dwelling adults, fair-skinned, Nambour Queensland
  • Exclusion criteria: not extracted; abstract-level no-fulltext-access

Intervention: sunscreen

Daily sunscreen arm subjects were supplied and instructed to apply SPF 15+ broad-spectrum sunscreen (protecting against both UVA and UVB) to head, neck, arms, and hands every morning, with reapplication after sweating or water exposure. The specific formulation used was described as SPF 16 in subsequent characterizations by Krutmann et al. (2021) 2, with limited UVA protection by modern standards. Discretionary controls used sunscreen at their own judgment, typically only for intentional sun exposure (beach, outdoor activities).

Intervention: beta-carotene supplement

Oral beta-carotene 30 mg/day capsule or matched placebo, taken over the 4.5-year follow-up. The beta-carotene dose represents a pharmacological dose approximately 6–10× higher than typical dietary intake. The rationale was that antioxidant supplementation might attenuate UV-induced oxidative damage to the dermis; the null result has direct implications for the uv-protection intervention page and the Krutmann exposome framework. 3

Follow-up duration

4.5 years (enrollment 1992–1996 within the Nambour Skin Cancer Study). This remains the longest-duration RCT measuring photoaging as an outcome.

Primary outcome

Microtopography of dermal elastosis on the dorsal hands — assessed by optical profilometry of silicone casts taken from a standardized dorsal-hand site. Silicone impressions capture surface microtopography; skin surface texture profiles are graded by trained dermatologists using standardized scales. The measure reflects the structural state of the dermis (dermal elastosis = accumulated elastotic material and collagen fragmentation from UV damage) as expressed at the skin surface. This is an objective histological-surrogate outcome, not a subjective wrinkle scale. 4

Baseline assessment was performed at enrollment; final assessment at trial end. The primary analytic comparison was the odds of any detectable increase in skin aging score at follow-up relative to baseline.

Key Findings

1. Daily sunscreen significantly reduced photoaging progression

Relative odds of detectable skin aging at follow-up (daily sunscreen vs. discretionary use):

OR 0.76 (95% CI 0.59–0.98)

This represents approximately 24% less skin aging in the daily sunscreen group — typically summarized as “24% less skin aging,” which is a valid simplification of the odds ratio. The CI excludes 1.0, indicating statistical significance at p < 0.05 (two-sided). 5

Importantly, participants in the daily sunscreen arm were assessed as having no detectable increase in skin aging over 4.5 years on the primary microtopography endpoint — a finding distinct from (and stronger than) simply demonstrating that they aged less than controls. This phrasing in secondary literature (“no detectable aging”) reflects the binary outcome design: the primary measure was whether aging progressed from baseline, not the magnitude of progression. no-fulltext-access — exact phrasing of primary endpoint analysis confirmed via secondary sources only; full outcome table not verified from PDF.

2. Beta-carotene supplementation showed no overall benefit for photoaging

The beta-carotene arm (30 mg/day for 4.5 years) produced no statistically significant reduction in photoaging on the primary outcome 5. The abstract notes “contrasting associations were seen in subgroups with different severity of aging at baseline” — the nature of these subgroup contrasts is not recoverable without full-text access. no-fulltext-access — subgroup findings by baseline severity not extracted. This null overall result is informative and has two important implications:

  • Oral antioxidant supplementation does not substitute for or augment topical UV protection for photoaging endpoints. Consistent with the broader antioxidant-supplementation literature where high-dose isolated beta-carotene failed to prevent cancer and (in smokers) increased cancer risk 6.
  • The beta-carotene null result was consistent with subsequent Krutmann exposome framing 3: the sun-aging problem requires a UV-blocking physical barrier, not systemic antioxidant rescue. Oral beta-carotene may provide some systemic photoprotective effect at the level of erythema threshold (MED), but this does not translate to photoaging prevention at the tissue level.

needs-replication — the null effect of oral beta-carotene on photoaging has been replicated indirectly (no major subsequent RCT has shown photoaging benefit from beta-carotene supplementation), but a dedicated confirmatory trial with modern outcome measures has not been published.

3. Effect size interpretation

The relative odds of 0.76 is the primary effect metric. A simple way to state this: in the daily sunscreen group, skin was ~24% less likely to show measurable photoaging progression over 4.5 years compared to discretionary users. The design does not produce a continuous effect size (millimeter changes in wrinkle depth, per-unit scoring scale difference) — it yields an odds ratio for a binary progression vs. non-progression outcome.

The dorsal-hand microtopography endpoint is a proxy for chronic UV-induced dermal elastosis, not a global facial wrinkle score or cosmetic outcome. Extrapolation to face/neck aesthetics is biologically justified but not directly tested here. 3

Limitations

1. Formulation vintage

The SPF 15–16 broad-spectrum sunscreen formulation used in this trial (1992–1996) had limited UVA-I protection by modern standards. Krutmann et al. (2021) 2 note that modern sunscreens with better UVA coverage and/or iron oxide pigments for visible-light protection may produce larger effects. The Hughes 2013 result is therefore likely a conservative estimate of what daily SPF 30+ broad-spectrum sunscreen with superior UVA-PF would achieve.

2. Discretionary control, not no-sunscreen

The control group used sunscreen “as they naturally would” — typically for recreational beach/outdoor exposure. This is a pragmatic real-world control, but it means the comparison is daily consistent use vs. intermittent recreational use, not sunscreen vs. no sunscreen. The absolute benefit of sunscreen vs. truly zero UV protection would be larger. This design choice is appropriate for the research question (does daily use add incremental protection over usual behavior?) and limits confounding by compliance.

3. Single anatomical site (dorsal hands)

The outcome was measured on the dorsal hands — a site with chronic, habitual UV exposure at lower intensity than the face. Whether the effect size generalizes to the face (highest aesthetic concern) or to photoprotected sites is not directly tested here.

4. Australian high-UV cohort

Queensland at latitude 26° S receives approximately 2–3× the annual UV dose of mid-latitude Northern Hemisphere locations (e.g., London, New York). Effect sizes may be smaller in lower-UV environments — though the mechanistic basis for UV photoaging applies at all latitudes where daily ambient UV exposure occurs.

5. 4.5-year time horizon

Though the longest photoaging RCT ever conducted, 4.5 years is short relative to the lifetime accumulation of UV damage. The full benefit of consistent daily sunscreen use over 20–40 years is not captured and cannot be ethically studied in a controlled design. long-term-unknown

6. Closed-access; abstract-level verification only

The full text is behind a paywall (Annals of Internal Medicine; not OA as of 2026). This study page is derived from the abstract, secondary descriptions in verified sources [^krutmann2017, ^krutmann2021, ^uv_protection_page], and the R42 UV-protection verifier cross-check. Methodological details (randomization procedure, allocation concealment, specific scoring rubric, per-arm n, per-arm dropout rates) were not directly verified from the PDF. no-fulltext-access

Significance and Downstream Impact

Hughes 2013 established daily broad-spectrum sunscreen as the best-evidenced single anti-photoaging intervention in humans — a conclusion that has held for over a decade without being superseded by a larger or longer RCT. It is the empirical anchor for:

  • krutmann-2017-skin-aging-exposome — cited as the definitive adult RCT; the review’s recommendation of daily sunscreen rests primarily on this paper.
  • uv-protection — primary clinical evidence section; OR 0.76 is the headline result.
  • The exposome framework conclusion that UV protection must be physical/topical (not supplementation-based), because the beta-carotene null result rules out oral antioxidant strategy as a substitute.

The factorial design yielding a null beta-carotene result is often underreported in secondary literature that focuses only on the sunscreen effect. Both findings together define the trial’s contribution: block the UV; don’t try to rescue the oxidative aftermath with oral supplements.

The 186 citations and 100th-percentile FWCI (Dermatology field) reflect the paper’s role as the foundational human-evidence anchor for a large evidence field.

Extrapolation Note

This study IS direct human RCT evidence. No model-organism extrapolation table is needed. All findings are from adult humans in a community-based trial. The intervention (topical sunscreen) is directly applicable to human populations. The only cross-species extrapolation issue in this paper’s surrounding literature is whether animal or in vitro mechanistic findings (AP-1/NF-κB → MMP cascade; Fisher 1996 1) generalise to humans — which they do (the Fisher 1996 study itself is human in vivo; this is a direct human RCT on the same outcome variable).

Knowledge Gaps

  • #gap/no-fulltext-access — Full PDF not available (closed-access); methodological details not directly verified.
  • #gap/long-term-unknown — 4.5-year trial cannot capture lifetime cumulative sunscreen benefit; no ethical pathway for a matched longer-duration controlled design.
  • #gap/needs-replication — No subsequently published RCT has directly replicated the Hughes 2013 result with a modern broad-spectrum SPF 30+ formulation and a broader anatomical assessment (face + hands); the intervention page cites Rönsch 2021 systematic review as supporting evidence but that review includes heterogeneous endpoints.
  • #gap/dose-response-unclear — SPF 15 vs. SPF 30 vs. SPF 50 for photoaging prevention has not been directly compared in an adequately powered RCT; whether higher SPF produces proportionally greater photoaging protection is inferred from dose-response modeling, not from a head-to-head trial.

Cross-References

  • uv-protection — intervention page anchored to this trial
  • krutmann-2017-skin-aging-exposome — review that synthesizes this RCT as its primary evidence
  • fisher-1996-photoaging-ap1-mmp — mechanistic basis for UV photoaging (AP-1/NF-ÎşB → MMP cascade) at sub-erythemogenic doses; the biological underpinning for why daily sunscreen prevents photoaging
  • skin-aging — phenotype hub; dermal elastosis as the clinical endpoint
  • dermis — site of UV-induced elastotic material accumulation
  • epidermis — UV entry portal; keratinocyte-mediated AP-1 response
  • dermal-fibroblasts — primary effector cells of dermal elastosis; MMP-mediated collagen fragmentation
  • genomic-instability — UV-induced CPD and 6-4PP photoproducts; MMP-1/3/9 cascade
  • loss-of-proteostasis — collagen degradation, elastin fragmentation, cross-linked AGE accumulation in dermis

Footnotes

Footnotes

  1. fisher-1996-photoaging-ap1-mmp · n=6–17 (varies by experiment) · in-vivo · p<0.01–0.025 depending on endpoint · model: human buttock skin in vivo; UV dose range 0.01–2 MED ↩ ↩2

  2. doi:10.1111/phpp.12683 · Krutmann J, Schalka S, Watson REB, Wei L, Morita A · Photodermatol Photoimmunol Photomed 2022;38(3):201–209 · review · model: human (clinical expert consensus + RCT synthesis); advocates SPF ≥30 + high UVA-PF + iron-oxide pigment as current standard · needs-replication — recommendations exceed direct RCT evidence base (no head-to-head trial of SPF 30 vs SPF 15 for photoaging endpoints) ↩ ↩2

  3. krutmann-2017-skin-aging-exposome · n=N/A · review · model: human skin (synthesis of epidemiological + in vitro + clinical studies); 669 citations; FWCI 24.8 ↩ ↩2 ↩3

  4. The exact scoring rubric for silicone-cast microtopography grading, inter-rater reliability statistics, and the specific profilometry parameters are not recoverable from abstract-level access. no-fulltext-access — full methodology pending PDF verification. ↩

  5. doi:10.7326/0003-4819-158-11-201306040-00002 · Hughes MCB, Williams GM, Baker P, Green AC · Ann Intern Med 2013;158(11):781–790 · n=903 · rct · 2×2 factorial · p<0.05 (OR 0.76; 95% CI 0.59–0.98) · model: adults aged 25–55, Queensland Australia; 4.5-year follow-up · no-fulltext-access — closed access; not downloaded ↩ ↩2

  6. doi:10.1056/NEJM199601043340101 · Omenn GS, Goodman GE, Thornquist MD et al. (CARET study) · N Engl J Med 1996;334(18):1150–1155 · rct · n=18,314 · beta-carotene + retinyl palmitate vs placebo in high-risk smokers; 28% more lung cancer, 17% more deaths in supplement group · model: human (high-risk for lung cancer — smokers + asbestos workers) ↩

Graph View